Pathogen-reduction technology, good in more than one way for cellular blood components, is replacing irradiation

被引：0

作者：

Flegel, Willy Albert ^{[1
,2
]}

机构：

[1] NIH Clin Ctr, Dept Transfus Med, NIH, Bethesda, MD USA

[2] Georgetown Univ, Dept Pathol, Med Ctr, Washington, DC USA

来源：

TRANSFUSION AND APHERESIS SCIENCE | 2025年 / 64卷 / 02期

基金：

美国国家卫生研究院;

关键词：

Platelet component; Transfusion-associated graft-versus-host dis-; ease; HLA; haplotype; VERSUS-HOST-DISEASE; TRANSFUSION; CELLS; PLATELETS; INACTIVATION; RIBOFLAVIN; EFFICACY; PLASMA; LIGHT;

D O I：

10.1016/j.transci.2025.104088

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical application of pathogen-reduction technology (PRT) is often restricted to platelet and non-cellular components, representing a minor fraction of the overall blood supply. The greatest benefit for patient safety may eventually derive from PRT in red cells, which is still unavailable for routine use. PRT is more effective to inactivate leukocytes than current irradiation, particularly pertinent for Japan with the only universal irradiation of cellular blood components. Elsewhere, only vulnerable patient cohorts are receiving irradiated cellular components. Blood components treated with approved PRT systems are exempt from irradiation if the patient requires irradiated components. Transfusion medicine has a strategic opportunity to develop and eventually utilize PRT for all cellular components, other than hematopoietic progenitor cell products. PRT would then enable leukocyte inactivation for 100 % of the blood supply, beneficial for transfusion safety in all patients.

引用

页数：3

共 47 条

[1]

[Anonymous], 2007, Vox Sang, V92, P160

[2]

[Anonymous], 2024, Vox Sang

[3] Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs.-host disease in Japan [J].

Asai, T ;

Inaba, S ;

Ohto, H ;

Osada, K ;

Suzuki, G ;

Takahashi, K ;

Tadokoro, K ;

Minami, M .

TRANSFUSION MEDICINE, 2000, 10 (04) :315-320

[4] Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026) [J].

Atreya, Chintamani ;

Glynn, Simone ;

Busch, Michael ;

Kleinman, Steve ;

Snyder, Edward ;

Rutter, Sara ;

AuBuchon, James ;

Flegel, Willy ;

Reeve, David ;

Devine, Dana ;

Cohn, Claudia ;

Custer, Brian ;

Goodrich, Raymond ;

Benjamin, Richard J. ;

Razatos, Anna ;

Cancelas, Jose ;

Wagner, Stephen ;

Maclean, Michelle ;

Gelderman, Monique ;

Cap, Andrew ;

Ness, Paul .

TRANSFUSION, 2019, 59 (09) :3002-3025

[5] Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction [J].

AuBuchon, JP ;

Herschel, L ;

Roger, J ;

Taylor, H ;

Whitley, P ;

Li, JZ ;

Edrich, R ;

Goodrich, RP .

TRANSFUSION, 2005, 45 (08) :1335-1341

[6] Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial [J].

Brixner, Veronika ;

Bug, Gesine ;

Pohler, Petra ;

Kraemer, Doris ;

Metzner, Bernd ;

Voss, Andreas ;

Casper, Jochen ;

Ritter, Ulrich ;

Klein, Stefan ;

Alakel, Nael ;

Peceny, Rudolf ;

Derigs, Hans G. ;

Stegelmann, Frank ;

Wolf, Martin ;

Schrezenmeier, Hubert ;

Thiele, Thomas ;

Seifried, Erhard ;

Kapels, Hans-Hermann ;

Doescher, Andrea ;

Petershofen, Eduard K. ;

Mueller, Thomas H. ;

Seltsam, Axel .

HAEMATOLOGICA, 2021, 106 (04) :1086-1096

[7] Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage [J].

Cancelas, Jose A. ;

Genthe, Jamie R. ;

Stolla, Moritz ;

Rugg, Neeta ;

Bailey, S. Lawrence ;

Nestheide, Shawnagay ;

Shaz, Beth ;

Mack, Samantha ;

Schroeder, Kadi ;

Anani, Waseem ;

Szczepiorkowski, Zbigniew M. ;

Dumont, Larry J. ;

Yegneswaran, Subramanian ;

Corash, Laurence ;

Mufti, Nina ;

Benjamin, Richard J. ;

Erickson, Anna C. .

TRANSFUSION, 2022, 62 (08) :1619-1629

[8] Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease [J].

Castro, Grace ;

Merkel, Patricia A. ;

Giclas, Hannah E. ;

Gibula, Andrew ;

Andersen, Gillian E. ;

Corash, Laurence M. ;

Lin, Jin Sying ;

Green, Jennifer ;

Knight, Vijaya ;

Stassinopoulos, Adonis .

TRANSFUSION, 2018, 58 (06) :1506-1515

[9] FDA approach to evaluation of pathogen reduction technology [J].

Epstein, JS ;

Vostal, JG .

TRANSFUSION, 2003, 43 (10) :1347-1350

[10] Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-γc-/- double knockout mice [J].

Fast, Loren D. ;

DiLeone, Gilbert ;

Cardarelli, Gene ;

Li, Junzhi ;

Goodrich, Raymond .

TRANSFUSION, 2006, 46 (09) :1553-1560

← 1 2 3 4 5 →